Abstract
Objective Several tissues produce and release interleukin-6 (IL-6) in response to beta(2)-adrenergic stimulation with selective agonists (beta(2)-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta(2)-agonists regulate skeletal muscle production and release of IL-6 in humans in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta(2)-agonist salbutamol in lean young men at rest and in recovery from resistance exercise. Design The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 11/2 h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and 1/2-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected 1/2 and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-alpha. Results Average leg IL-6 release was 1.7-fold higher (p = 0.01) for salbutamol than placebo, being 138 +/- 76 and 79 +/- 66 pg min(-1) (mean +/- SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5- and 1.7-fold higher (p = 0.001) for salbutamol than placebo 1/2 and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-alpha mRNA. Conclusions Beta(2)-adrenergic stimulation with high doses of the selective beta(2)-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise, and increases muscle IL-6 release in lean individuals.
Funding Information
  • Kulturministeriet

This publication has 63 references indexed in Scilit: